Rapid radioimmunoassay for prostate-specific acid phosphatase in human serum.

1980 ◽  
Vol 26 (11) ◽  
pp. 1544-1547 ◽  
Author(s):  
P Vihko ◽  
A Kostama ◽  
O Jänne ◽  
E Sajanti ◽  
R Vihko
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Reference Group ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Serum Concentrations ◽  
Healthy Men ◽  
Monospecific Antisera ◽  
Group Serum

Abstract We describe a rapid radioimmunoassay for human prostatic acid phosphatase (EC 3.1.3.2) in serum, with use of monospecific antisera raised in rabbits against the primary highly purified acid phosphatase (pl 4.9) from human prostates, and with a second antibody-polyethylene glycol porecipitation. This radioimmunoassay is sensitive and can be performed within 5 h. Concentrations of the immunoreactive acid phosphatase in sera of healthy men (n = 394) ranged from 0.3 to 3.6 microgram/L (mean 1.94, SD 0.66 microgram/L). Concentrations of the enzyme in sera of men with benign prostatic hyperplasia (n = 56) or with carcinoma of nonprostatic origin (n = 24) were identical with those of the reference group. Serum concentrations of immunoreactive prostatic acid phosphatase of patients with occult, non-metastatic, and metastatic prostatic carcinoma varied from 1.7 to 9.3 (n = 9), 4.2 to 59.4 (n = 12), and 20 to 198 (n = 10) microgram/L, respectively. The amount of immunoassayable prostatic acid phosphatase was unchanged for at least five days in serum stored at 4 degrees C.

Measurement of prostate-specific antigen and prostatic acid phosphatase concentrations in serum before and 1-42 days after transurethral resection of the prostate and orchidectomy

1991 ◽  
Vol 37 (6) ◽  
pp. 859-863 ◽  
Author(s):  
Alun Price ◽  
Stephen E A Attwood ◽  
jhon B F Grant ◽  
Trevour A Gray ◽  
Kenneth T H Moore
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Prostate Specific Antigen ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Antigen Concentration ◽  
The Third ◽  
Diagnostic Usefulness

Abstract Preoperative intra-individual variation for determinations of prostate-specific antigen and prostatic acid phosphatase concentrations, 15-30% in 92 patients with benign prostatic hyperplasia, limits the diagnostic usefulness of both tumor markers. In benign prostatic hyperplasia (214 patients), concentrations of these tumor markers increased in the initial postoperative period. Prostatic acid phosphatase concentration then decreased by the third postoperative day. Prostate-specific antigen concentration remained above normal in the first postoperative week but had decreased by 42 days. In prostatic carcinoma (46 patients), the concentrations of these tumor markers did not increase postoperatively. During the first week, the concentrations of prostatic acid phosphatase began to fall, but prostate-specific antigen showed a decrease only at 42 days. After orchidectomy (11 patients), the concentrations of both markers had decreased by five days. Concentrations of prostate-specific antigen but not of prostatic acid phosphatase were significantly increased in patients with metastases at 42 days postoperatively. When the concentration of tumor marker did decrease, the magnitude of change was greater for prostatic acid phosphatase than for prostate-specific antigen. These changes were accentuated after an orchidectomy.

Acid phosphatase in prostatic tissue homogenates from patients with benign prostatic hyperplasia and prostatic carcinoma

Cancer ◽  
2006 ◽  
Vol 52 (1) ◽  
pp. 155-160 ◽  
Author(s):  
Gary T. Copland ◽  
Garnett B. Whitehurst ◽  
Theresa P. Pretlow ◽  
Emily A. Boohaker ◽  
Alfred A. Bartolucci ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Prostatic Hyperplasia ◽  
Prostatic Tissue ◽  
Tissue Homogenates

Serum prostate-specific acid phosphatase: development and validation of a specific radioimmunoassay.

1978 ◽  
Vol 24 (11) ◽  
pp. 1915-1919 ◽  
Author(s):  
P Vihko ◽  
E Sajanti ◽  
O Jänne ◽  
L Peltonen ◽  
R Vihko
Keyword(s):  
Acid Phosphatase ◽  
Reference Group ◽  
Prostatic Acid Phosphatase ◽  
Human Spleen ◽  
Specific Radioimmunoassay ◽  
Chloramine T ◽  
Monospecific Antisera ◽  
Synovial Tissues ◽  
Development And Validation ◽  
Free Serum

Abstract We describe radioimmunoassay for human prostatic acid phosphatase [orthophosphoric-monoester phospho-hydrolase (acid optimum), EC 3.1.3.2] in serum, with use of monospecific antisera raised in rabbits against highly purified acid phosphatase from human prostates. The antiserum did not cross react with partly purified acid phosphatases from human spleen, erythrocytes, or synovial tissues. 125I-labeled acid phosphatase was prepared by a Chloramine T method, and the bound and free antigen was separated in the assay by use of anti-rabbit gamma-globulin raised in sheep. Uniform low nonspecific binding of the [125I]acid phosphatase was achieved by using acid-phosphatase-free serum to prepare standard curves and diluted samples of serum with high acid phosphatase activities. Concentrations of immunoreactive acid phosphatase in the serum of healthy men ranged from less than 1 to 10 microgram/liter and for 12 patients with advanced prostatic carcinoma between 100 and 500 microgram/liter. The concentrations of the enzyme in sera of patients with benign prostatic hyperplasia were very similar to those in sera of the reference group.

Comparison of enzyme-linked immunosorbent assay and radioimmunoassay for prostate-specific acid phosphatase in prostatic disease.

1982 ◽  
Vol 28 (1) ◽  
pp. 183-186 ◽  
Author(s):  
J Griffiths ◽  
D F Rippe ◽  
P R Panfili
Keyword(s):  
Acid Phosphatase ◽  
Benign Prostatic Hyperplasia ◽  
Immunosorbent Assay ◽  
Digital Rectal Examination ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Prostatic Adenocarcinoma ◽  
Enzyme Linked Immunosorbent Assay ◽  
Specific Enzyme ◽  
Prostatic Disease

Abstract We compared results by an enzyme-linked immunosorbent assay (ELISA) with those by a standard radioimmunoassay (RIA) for detection and quantitation of prostate-specific acid phosphatase (EC 3.1.3.2) in serum. Control subjects, patients with benign prostatic hyperplasia, and patients in all four clinical stages of prostatic adenocarcinoma were tested. The upper limit of normal (95% of the population) by the ELISA was 2.0 micrograms/L, and by the RIA was 2.2 micrograms/L. In prostatic adenocarcinoma stage I (not detectable by digital rectal examination), ELISA was slightly more sensitive than RIA, but sensitivity was still relatively low (20%). As tumor mass increased (stages II through IV), the frequency of increased concentrations of prostatic acid phosphatase in serum also increased. We confirmed this increase in circulating enzyme in some cases of benign prostatic hyperplasia and suggest that this finding is related to either acinar cytolysis or an increase in acini size and number. Although prostate-specific acid phosphatase is not a cancer-specific enzyme, we conclude that its measurement may be of considerable value in monitoring prostatic disease.

Serum Prostate-Specific Antigen Determination in Prostatic Carcinoma

1987 ◽  
Vol 2 (3) ◽  
pp. 184-186 ◽  
Author(s):  
Alessandro Tizzani ◽  
Giovanni Casetta ◽  
Paolo Piana ◽  
Maurizio Bellina ◽  
Ferdinando Pecchio ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Number Of Patients ◽  
Antigen Determination ◽  
Early Predictor

Prostate-specific antigen (PSA) is a tissue-specific glycoprotein identified by Wang in 1979. It is synthesized in the prostate independently of prostatic acid phosphatase (PAP). A total of 199 subjects were divided into four groups: controls aged less than 50 years, controls aged more than 50 years, patients with benign prostatic hyperplasia (BPH) and patients with prostatic carcinoma. PSA cut-off value was set at 10 ng/ml (mean for the BPH group plus 2 SD). With this cut-off value PSA could not be used as an early predictor of prostatic carcinoma. The association of PSA and PAP in prostatic cancer increases the number of patients with positive biological markers.

Prostatic Acid Phosphatase (PAP) Differentiated Ultracytochemically from Lysosomal Acid Phosphate in the Rat with a PAP/Specific Substrate, Phosphorylcholine

1975 ◽  
Vol 33 ◽  
pp. 450-451
Author(s):  
W. Allen Shannon ◽  
José A. Serrano ◽  
Hannah L. Wasserkrug ◽  
Anna A. Serrano ◽  
Arnold M. Seligman
Keyword(s):  
Acid Phosphatase ◽  
Phosphate Buffer ◽  
Prostatic Carcinoma ◽  
Prostatic Acid Phosphatase ◽  
Chemotherapeutic Agents ◽  
Specific Substrate ◽  
Acid Phosphate ◽  
Lysosomal Acid ◽  
Design And Synthesis ◽  
New Chemotherapeutic Agents

During the design and synthesis of new chemotherapeutic agents for prostatic carcinoma based on phosphorylated agents which might be enzyme-activated to cytotoxicity, phosphorylcholine, [(CH3)3+NCH2CH2OPO3Ca]Cl-, has been indicated to be a very specific substrate for prostatic acid phosphatase (PAP). This phenomenon has led to the development of specific histochemical and ultracytochemical methods for PAP using modifications of the Gomori lead method for acid phosphatase. Comparative histochemical results in prostate and kidney of the rat have been published earlier with phosphorylcholine (PC) and β-glycerophosphate (βGP). We now report the ultracytochemical results.Minced tissues were fixed in 3% glutaraldehyde-0.1 M phosphate buffered (pH 7.4) for 1.5 hr and rinsed overnight in several changes of 0.05 M phosphate buffer (pH 7.0) containing 7.5% sucrose. Tissues were incubated 30 min to 2 hr in Gomori acid phosphatase medium (2) containing 0.1 M substrate, either PC or βGP.

Prostatic Hexosaminidase Activity in Patients With Benign Prostatic Hyperplasia and Prostatic Carcinoma

1983 ◽  
Vol 130 (1) ◽  
pp. 193-193
Author(s):  
G.B. Whitehurst ◽  
J.P. Mashburn ◽  
T.G. Pretlow ◽  
E.L. Bradley ◽  
E.A. Boohaker
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Carcinoma ◽  
Prostatic Hyperplasia
Sign in / Sign up

Export Citation Format

Share Document